These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20196437)

  • 1. [Vaccine update 2009: questions around the safety of the influenza A (H1N1) vaccine].
    Siegrist CA
    Rev Med Suisse; 2010 Jan; 6(231):67-70. PubMed ID: 20196437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(48):1351-6. PubMed ID: 20010511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The safety and immunogenicity of the vaccines against pandemic (H1N1) 2009 influenza].
    Grotto I; Engelhard D
    Harefuah; 2009 Dec; 148(12):799-803, 857. PubMed ID: 20088428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on influenza A (H1N1) 2009 monovalent vaccines.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Oct; 58(39):1100-1. PubMed ID: 19816398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All health professionals should receive the 2009 H1N1 influenza vaccine.
    Seppelt IM; Webb SA; Booy R
    Crit Care Resusc; 2010 Mar; 12(1):3-5. PubMed ID: 20196706
    [No Abstract]   [Full Text] [Related]  

  • 6. H1N1 vaccine for prevention of pandemic influenza.
    Med Lett Drugs Ther; 2009 Oct; 51(1322):77-8. PubMed ID: 19798010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avoiding Guillan-Barré Syndrome following swine origin pandemic H1N1 2009 influenza vaccination.
    Eisen DP; McBryde ES
    J Infect Dis; 2009 Nov; 200(10):1627-8. PubMed ID: 19857155
    [No Abstract]   [Full Text] [Related]  

  • 8. Guillain-Barré syndrome following H1N1 immunization in a pediatric patient.
    Tremblay ME; Closon A; D'Anjou G; Bussières JF
    Ann Pharmacother; 2010; 44(7-8):1330-3. PubMed ID: 20484170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse of nephrotic syndrome following the use of 2009 pandemic influenza A (H1N1) vaccine.
    Fernandes P; Jorge S; Lopes JA
    Am J Kidney Dis; 2010 Jul; 56(1):185-6. PubMed ID: 20620684
    [No Abstract]   [Full Text] [Related]  

  • 10. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
    Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
    Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Guillain-Barre syndrome and the mass vaccination against A/H1N1. No increase of the risk has been reported so far].
    Press R; Andersen O
    Lakartidningen; 2010 Mar 10-16; 107(10):666-7. PubMed ID: 20402249
    [No Abstract]   [Full Text] [Related]  

  • 12. Seizures and retrograde amnesia with cerebrospinal fluid changes following H1N1 influenza vaccination.
    Mitrakrishnan S; Ranjanie G; Thirunavakarasu T; Manjula C; Nayananjani K
    Vaccine; 2011 Aug; 29(37):6369-70. PubMed ID: 21840464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Guillain-Barré syndrome secondary to H1N1 influenza vaccine].
    López Nieto M; Gómez Garrido J; Losa Palacios A; Aguila Manso G
    Rev Clin Esp; 2010 Oct; 210(9):485-6. PubMed ID: 20832792
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D
    J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effects following pandemic influenza (H1N1) 2009 vaccination.
    Bolam B; Grills N
    Aust N Z J Public Health; 2009 Dec; 33(6):584. PubMed ID: 20078579
    [No Abstract]   [Full Text] [Related]  

  • 16. The cost of H1N1. Payers hope vaccine availability will help ease costs.
    Vesely R
    Mod Healthc; 2009 Nov; 39(44):10. PubMed ID: 20135783
    [No Abstract]   [Full Text] [Related]  

  • 17. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza.
    Collin N; de Radiguès X;
    Vaccine; 2009 Aug; 27(38):5184-6. PubMed ID: 19563891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Selected problems of manufacturing influenza vaccines].
    Augustynowicz E
    Przegl Epidemiol; 2010; 64(3):373-80. PubMed ID: 20976949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intent to receive influenza A (H1N1) 2009 monovalent and seasonal influenza vaccines - two counties, North Carolina, August 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Dec; 58(50):1401-5. PubMed ID: 20032923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.